The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders
Open accessAbstract
Cyclin-dependent kinase 6 (CDK6) is an important regulator of the cell cycle. Together with CDK4, it phosphorylates and inactivates retinoblastoma (Rb) protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whereas multiple studies have described numerous CRBN-recruiting dual-selective degraders and CDK6-selective degraders 70–73, none report CDK4-selective degraders; the only reported CDK4-selective degraders are built on a slightly different warhead, ribociclib 74.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Meyers, R. M., Bryan, J. G., McFarland, J. M., Weir, B. A., Sizemore, A. E., Xu, H., Dharia, N. V., Montgomery, P. G., Cowley, G. S., Pantel, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3984 · Cited by 1,952
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Self-citationCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Flagged first, then by citations
Research works printed but not linked: 1
- Schumacher, 1965, Br. J. Pharmacol., 25, 324
Cited by
Sorted by citations
Items 101–153 of 153
Prospects and advances of PROTAC in the treatment of hematologic malignancies
Wang, X., Zhang, M., & Mei, H. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00759-3 · Cited by 3
Advantages of PROTACs in achieving selective degradation of homologous protein families
Yang, L., Mao, X., Zhang, J., Shu, J., Huang, W., Dong, X., Chen, Y., & Wu, M. (2026) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.22.49 · Cited by 3
PROteolysis TArgetting Chimeras (PROTACs) Strategy Applied to Kinases: Recent Advances
Feral, A., Laconde, G., Amblard, M., & Masurier, N. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000148 · Cited by 3
Ranjini Jenifer, R., Choudhury, B., Alam, M. M., Balamurali, M. M., & Chanda, K. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2491303 · Cited by 3
Unraveling the secrets of novel PROTACs to improve degradation efficacy
Huang, J., Yang, X., Huang, Q., Gao, Y., Bandaranayake, P. C. G., Kandegama, W. M. W. W., Ashby, C. R., Dong, Y., Wang, Z., & Hao, G. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11273-9 · Cited by 3
Discovery of WWZ-11-098: a rigid and selective CDK6 degrader
Zhang, W., Wen, J., Wu, Y., Xuan, Y., Han, Q., Chen, X., Yu, J., Yu, H., & Jiang, B. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118569 · Cited by 2
A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II Inhibition
Kim, J. H., Mills, C. E., Kozicka, Z., Scott, D. C., Jin, C., Jiang, Z., Dwyer, B. G., Geng, Q., Toenjes, S. T., Byun, W. S., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c10277 · Cited by 2
Pilania, P., Nandi, S., Meena, D. K., & Sharma, B. K. (2024) · Current Signal Transduction Therapy · doi:10.2174/0115743624279638240211170045 · Cited by 1
Wu, Y., Xu, Z., Kou, Z., Ye, Q., Chen, L., & Gou, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-11043-5 · Cited by 1
Degraders of cell cycle- and antiapoptosis-related proteins
Zhang, Y., Dong, R., & Zhang, B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21816-3.00002-6 · Cited by 1
Yang, J., Qiao, Q., Lin, N., Niu, M., Su, L., & Yin, B. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70427 · Cited by 2
PROTAC-based protein degradation: a window of opportunity for melanoma therapy
Gentile, G., D’Aguanno, S., Martile, M. D., Petricca, A., Valentini, E., Scalera, S., & Bufalo, D. D. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01225-2 · Cited by 1
First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria
Macicior, J., Telechea, M., Fernández, D., García-Martín, A., Canales, Á., & Ortega‐Gutiérrez, S. (2026) · Advanced Science · doi:10.1002/advs.202521608 · Cited by 2
Sosič, I., Gobec, M., Steinebach, C., Schlesinger, M., Bendas, G., & Gütschow, M. (2021) · Archiv der Pharmazie · doi:10.1002/ardp.202100151 · Cited by 1
Self-citationPROTACs in the Management of Prostate Cancer
Mandlik, D. S., & Mandlik, S. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_11 · Cited by 1
The 2nd Alpine Winter Conference on Medicinal and Synthetic Chemistry
Ciulli, A., Hamann, L. G., Jahnke, W., Kalgutkar, A. S. S., Magauer, T., Ritter, T., Steadman, V., Williams, S. D., Winter, G. E., Hoegenauer, K., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100372
Adhikari, B., Schneider, K., Diebold, M., Sotriffer, C., & Wolf, E. (2024) · eLife · doi:10.7554/elife.98450.1
Adhikari, B., Schneider, K., Diebold, M., et al. (2024) · eLife · doi:10.7554/elife.98450.1.sa1
Adhikari, B., Schneider, K., Diebold, M., et al. (2024) · eLife · doi:10.7554/elife.98450.1.sa0
PROTACs of cyclin-dependent kinases
Veselá, D., Řezníčková, E., Mik, V., & Jorda, R. (2024) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2024.10.003
Adhikari, B., Schneider, K., Diebold, M., Sotriffer, C., & Wolf, E. (2024) · eLife · doi:10.7554/elife.98450.2
Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer
Zhao, K., Zhang, J., Yang, Z., Wang, R., Shi, Y., Ji, Y., Zhang, S., & Liu, M. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s527906 · Cited by 1
Optochemical control of G1 cell cycle by regulating CDK4/6 degradation
Wang, T., Zhang, Y., Liu, Y., Wang, L., Liu, L., & Wang, W. (2025) · iScience · doi:10.1016/j.isci.2025.113304
Huang, X., Jayabalan, D. S., Liberto, M. D., Chen, Z., Ely, S. A., Mark, T. M., Lin, G., Niesvizky, R., & Chen‐Kiang, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.14.681840
PROTACS- targeted protein degradation as a path to precision cancer therapeutics
Gatley, H. R., Fisher, P. B., & Das, S. K. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.08.001
Maksutova, A. I., Geiger, T. M., Cianni, L., Pieńkowska, D. E., Gerhartz, J., Read, L., Bricelj, A., Herrmann, A., Nelles, M. L., Ng, Y. L. D., et al. (2025) · ChemMedChem · doi:10.1002/cmdc.202500929
Self-citationDegradation of Cyclin-Dependent Kinase: A New Weapon for Cancer Therapy
Tian, X., Dai, X., Zhong, Y., Cheng, M., & Liu, Y. (2025) · Pharmaceutical Fronts · doi:10.1055/a-2742-7859
Wang, C., Lin, J., Pei, J., Kang, Z., Liu, Z., Li, J., Cai, G., Zhou, Y., Wang, J., Wang, H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03442
Xu, Y., Wang, S., Saneyoshi, H., Fujita, H., & Nagasawa, K. (2026) · Research Square · doi:10.21203/rs.3.rs-9143133/v1
Zhang, Y., Kan, C., Ai, J., Zhou, R., Zhao, Q., Gao, J., Wang, Y., Wu, Z., Qin, X., Ma, J., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119065
Tsymliakov, M., Hanl, M., Enns, J., Zhai, S., Ferretti, E., König, P., Kousa, R., Tu, J., Steinebach, C., Gütschow, M., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c02045 · Cited by 1
Self-citationAdamlje, B., Tomašič, T., Steinebach, C., Ebeling, S., Herrmann, A., Hartmann, M. D., Horner, J. L., Bhadresha, K. P., Chau, C. H., Figg, W. D., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.70360
Self-citationDiscovery of rigid linker-based CDK4/6 PROTACs for the treatment of breast cancer
Pan, G., Li, Y., Tan, J., Chen, Y., Chen, W., Yang, H., Zhuang, X., Shen, L., Zong, Z., Fan, Y., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110368
Huang, X., Jayabalan, D. S., Liberto, M. D., Chen, Z., Ely, S. A., Mark, T. M., Lin, G., Niesvizky, R., & Chen‐Kiang, S. (2026) · Blood Neoplasia · doi:10.1016/j.bneo.2026.100285
CDK4/6 inhibitors: drug discovery, development, and classification
Gupta, S., Chahat, Kumar, B., Kumar, M., Wahajuddin, M., & Joshi, G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44611-5.00004-3
Expanding the E3 Ligase Landscape: From Small Molecule to Biological Targeted Protein Degradation
Zhao, X., Liu, Y., & Teng, X. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_842
PROTACs in Oncology: Emerging Frontiers for Next-Generation Cancer Therapeutics
Salahuddin, S., Sharma, R., Ahsan, M. J., Mazumder, A., Rana, K., Kumar, R., & Majee, C. (2026) · Onco · doi:10.3390/onco6030048
Nafees, S., Alasiri, G. A., Akhter, M. S., & Ali, N. (2026) · Cancer Gene Therapy · doi:10.1038/s41417-026-01082-z
BindingDB Entry 50018659: Developments of CRBN-based PROTACs as potential therapeutic agents.
BindingDB (2024) · UC San Diego · doi:10.7270/q27948wc
BindingDB (2023) · UC San Diego · doi:10.7270/q2vm4h9b
BindingDB Entry 50018797: A bibliometric analysis of PROTAC from 2001 to 2021.
BindingDB (2024) · UC San Diego · doi:10.7270/q28p64s7
BindingDB Entry 50015903: Encoding BRAF inhibitor functions in protein degraders.
BindingDB (2023) · UC San Diego · doi:10.7270/q2x92g87
BindingDB (2022) · UC San Diego · doi:10.7270/q2wm1j1b
BindingDB (2024) · UC San Diego · doi:10.7270/q2vh5t9d
BindingDB (2024) · UC San Diego · doi:10.7270/q2pv6qt5
Metadata
- Authors
- Steinebach, C., Ng, Y. L. D., Sosič, I., Lee, C.-S., Chen, S., Lindner, S., Vu, L. P., Bricelj, A., Haschemi, R., Monschke, M., Steinwarz, E., Wagner, K. G., Bendas, G., Luo, J., Gütschow, M., & Krönke, J.
- Affiliations
- University of Bonn (DE)
- Universität Ulm (DE)
- University of Ljubljana (SI)
- National Cancer Institute (US)
- Corresponding author
- Gütschow, Michael
- Krönke, Jan
- ORCID
- Venue
- Chemical Science
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2020
- Volume
- 11
- Issue
- 13
- Pages
- 3474-3486
- ISSN
- 2041-6520 (ISSN-L)
- 2041-6539
- PMC
- PMC7552917
- OpenAlex
- W3009753365
- Cited by
- 148
- References
- 77
- Citations by year
- 2026: 20 · 2025: 24 · 2024: 27 · 2023: 20 · 2022: 27 · 2021: 22 · 2020: 8
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Chemical Science (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (FOR2372, Kr-3886/2-1, SFB1074)
- Javna Agencija za Raziskovalno Dejavnost RS (P1-0208)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, CDK4/6, E3 ubiquitin ligase, VHL, cIAP1, targeted protein degradation, tumor cell proliferation, leukemia, multiple myeloma, breast cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
